Articles Tagged With: Vocabria
-
Cabotegravir Extended-Release and Rilpivirine Injectable Suspension (Cabenuva) and Cabotegravir Tablets (Vocabria)
Cabotegravir/rilpivirine (CAB/RPV) should be prescribed to treat HIV-1-infected adults. This combination should replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable regimen with no history of treatment failure and no known or suspected resistance to ether CAB or RPV.